G43.001 Insurance Policy Changes

ICD-10 G43.001 is officially defined as "Migraine without aura, not intractable, with status migrainosus." code G43.001 is referenced in 17 tracked payer policy changes from Independence Blue Cross and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G43.001 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Jan 1, 2026Medium impact
MA05.071, Remote Electrical Neuromodulation for Migraines
Independence Blue Cross reissued MA05.071 with no substantive changes to Remote Electrical Neuromodulation (REN/Nerivio) coverage for migraine prevention. The policy establishes medical necessity criteria for adults (18+) and pediatric patients (8-17) with 6-24 headache days per 28-day period, requiring either failed preventive medications, pregnancy/breastfeeding status, medication overuse headache risk, or drug-drug interaction concerns. Acute migraine treatment remains non-covered (experimental/investigational). Billing teams must ensure claims comply with these eligibility criteria and HCPCS code A4540 is used for device billing.
Independence Blue Cross · Effective Jan 1, 2026Medium impact
05.00.86, Remote Electrical Neuromodulation for Migraines
Independence Blue Cross has upgraded Remote Electrical Neuromodulation (REN) devices like Nerivio from Experimental/Investigational to Medically Necessary for migraine prevention in adults (18+) and pediatric patients (8-17) who meet specific clinical criteria, including migraine frequency of 6-24 headache days per 28-day period and failure of or contraindication to preventive medications. This policy is effective January 1, 2026, and represents a significant coverage expansion that will allow claims for previously denied devices.
Aetna · Identified Oct 22, 2026Medium impact
Ziconotide (Prialt) (CPB 0712, reviewed 2026-10-14)
Aetna considers intrathecal ziconotide (Prialt) medically necessary for members with severe chronic pain that is intolerant of or refractory to other treatments, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Aetna considers it not medically necessary for members with a pre-existing history of psychosis, an infection at the micro-infusion injection site, uncontrolled bleeding diathesis, or spinal canal obstruction. Aetna considers intrathecal ziconotide experimental, investigational, or unproven for autism, epilepsy, Irukandji syndrome, migraines, primary lateral sclerosis, stroke and other indications, and considers the intrathecal combination of ziconotide, morphine and levobupivacaine experimental for cancer-related refractory pain.
Aetna · Identified Oct 21, 2026Medium impact
Intra-oral Appliances for Headaches and Trigeminal Neuralgia (CPB 0688, reviewed 2026-10-14)
Aetna considers intra-oral appliances, such as the Nociceptive Trigeminal Inhibition-Tension Suppression System, experimental, investigational, or unproven for treating headaches and trigeminal neuralgia, because the effectiveness of this approach for these indications has not been established. CPT 21110 and HCPCS codes for occlusal guards, removable appliance therapy, custom sleep apnea appliances, and oral appliance therapy are listed as not covered for the indications in this policy. Diagnosis codes for migraine, other headache syndromes, trigeminal neuralgia, and headache are also listed as not covered for the indications in this policy.
Aetna · Identified Oct 16, 2026Medium impact
Eptinezumab-jjmr (Vyepti) (CPB 0970, reviewed 2026-10-14)
Aetna covers eptinezumab-jjmr (Vyepti) for commercial medical plans, and precertification of Vyepti is required for Aetna participating providers and members in applicable plan designs. Aetna considers Vyepti medically necessary for preventive treatment of migraine in an adult member who has not received at least 3 months of treatment with the requested medication. Aetna considers continuation medically necessary for adult members requesting reauthorization for preventive treatment of migraine when the member has received at least 3 months of treatment and had a reduction in migraine days per month from baseline. Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Oct 5, 2026Medium impact
Therapeutic Phlebotomy (CPB 0652, reviewed 2026-09-25)
Aetna considers therapeutic phlebotomy medically necessary for erythrocytosis of undetermined etiology with a hematocrit of 55% or higher, hemochromatosis (including hereditary hemochromatosis), individuals receiving testosterone therapy with a hematocrit of 54% or higher (or hemoglobin of 180 g/L or higher), non-alcoholic fatty liver disease with hyperferritinemia, non-hereditary hemochromatosis iron overload with elevated hepatic iron concentration, polycythemia vera, polycythemia secondary to arteriovenous fistulae, cor pulmonale or cyanotic congenital heart disease (for hematocrit greater than 60%), porphyria cutanea tarda, and sickle cell crisis. The policy lists acute gouty arthritis, chronic hepatitis C, chronic urticaria, the common cold, hyperferritinemia in alcohol liver disease, hypertension, migraines, myeloproliferative disorders without polycythemia vera, and progressive multiple sclerosis as experimental, investigational or unproven for phlebotomy treatment. CPT 99195 (phlebotomy, therapeutic, separate procedure) is covered if the selection criteria are met.
Aetna · Identified Oct 5, 2026Medium impact
Infrared Therapy (CPB 0604, reviewed 2026-09-09)
Aetna considers infrared coagulation medically necessary for anal dysplasia and for members with grade I, II, or III internal hemorrhoids that are painful or persistently bleeding. Low-level infrared light therapy is considered experimental, investigational, or unproven for a long list of indications, including osteoarthritis, migraines, stroke, and diabetes mellitus, and the infrared glove is unproven for Raynaud's syndrome and all other indications. CPT 46930 is covered when selection criteria are met, while CPT 97026 and HCPCS codes A4639 and E0221 are not covered for the listed indications.
Aetna · Identified Aug 19, 2026Medium impact
Neuropsychological and Psychological Testing (CPB 0158, reviewed 2026-03-20)
Aetna covers neuropsychological testing when it is needed to assess cognitive impairment due to medical or psychiatric conditions, provided the hours or units requested do not exceed the reasonable time needed to address the clinical questions, the testing techniques are validated for the proposed diagnostic question and for the member's age and population, and the testing does not repeat measurements of the same domain. Neuropsychological testing requested for a mental health diagnosis is considered for coverage through the mental health benefit, and testing requested for a medical diagnosis such as traumatic brain injury, stroke, epilepsy or Alzheimer's disease is considered under the medical benefit. Testing performed for educational, employment, disability qualification or legal or court-related purposes is not covered, and computerized neuropsychological assessment devices such as Cognitrax are considered experimental for screening asymptomatic people and for other indications, including screening and monitoring multiple sclerosis-related cognitive impairment.
Aetna · Identified Aug 18, 2026Medium impact
Hospitalization for the Initiation of Ketogenic Diet (CPB 0226, reviewed 2026-04-23)
Aetna considers hospitalization for initiation of a ketogenic diet medically necessary for intractable seizures, including Doose syndrome and Lennox-Gastaut syndrome, when all listed selection criteria are met, and for persons with glucose transporter protein type 1 deficiency or pyruvate dehydrogenase complex deficiency. Aetna considers hospitalization for initiation of a ketogenic diet of unproven value for all other indications, including adult super-refractory status epilepticus, Alzheimer's disease, autism spectrum disorder, cancer, migraine prevention, multiple sclerosis, Parkinson's disease, schizophrenia and type 2 diabetes. Hospitalization for initiation of the Atkins diet for intractable seizures, mitochondrial diseases, or other indications is considered experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Headaches: Nonsurgical Management (CPB 0462, reviewed 2026-07-23)
Aetna covers intravenous dihydroergotamine (DHE) for status migrainosus, for other intractable severe migraine attacks unresponsive to analgesics and triptans, and for cluster headache attacks that do not respond to oxygen or triptans, when given in the emergency room, hospital or urgent care setting, and covers it for medication overuse headache in the inpatient setting. Aetna also covers intramuscular ketorolac for short-term management of acute migraine (5 days or less), intramuscular and intravenous steroids and intravenous magnesium for acute migraines, caffeine citrate infusion for post lumbar puncture headache when the member is unable to take caffeine orally, and eptinezumab-jjmr (Vyepti) for preventive migraine treatment in an adult when the criteria are met. Aetna considers cranio-sacral therapy, intra-oral splints for tension-type headaches, IV DHE for other headache types, and a list of other nonsurgical migraine and cluster headache interventions experimental, investigational or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Fecal Bacteriotherapy (CPB 0844, reviewed 2026-03-25)
Aetna's commercial clinical policy bulletin 0844 covers fecal bacteriotherapy. It considers fecal microbiota transplant medically necessary for Clostridium difficile infection (CDI) confirmed by a positive C. difficile toxin stool test that has recurred after at least one course of adequate antibiotic therapy. It considers a single rectal dose of Rebyota (fecal microbiota, live-jslm) medically necessary for preventing CDI when the policy's criteria are met, and it considers other listed indications, including alcoholic hepatitis, Crohn's disease, ulcerative colitis and irritable bowel syndrome, experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Eptinezumab-jjmr (Vyepti) (CPB 0970, reviewed 2025-12-09)
This Aetna policy addresses Vyepti (eptinezumab-jjmr) for commercial medical plans and requires precertification from Aetna participating providers and members in applicable plan designs. Aetna considers Vyepti medically necessary for preventive treatment of migraine in an adult member who has not received at least 3 months of treatment with the requested medication, and considers continuation medically necessary for adults who have received at least 3 months of treatment and had a reduction in migraine days per month from baseline. The recommended dosage is 100 mg given as an intravenous infusion over approximately 30 minutes every 3 months, some individuals may benefit from 300 mg every 3 months, and all other indications are considered experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-06-03)
Aetna considers TENS medically necessary durable medical equipment as an adjunct or alternative to drugs for acute post-operative pain in the first 30 days after surgery, or for certain chronic intractable pain not adequately responsive to other methods such as physical therapy and pharmacotherapy. Peripherally implanted nerve stimulators are considered medically necessary for intractable neuropathic pain when the member meets all listed criteria, including a successful percutaneous stimulation trial that resulted in at least a 50% reduction in pain for a minimum of 3 days. TENS for chronic low back pain, PENS for opioid withdrawal, and many other electrical stimulation devices and indications are considered experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Biofeedback (CPB 0132, reviewed 2026-07-16)
Aetna considers biofeedback medically necessary for cancer pain, chronic constipation secondary to dyssynergic defecation as confirmed by anorectal manometry, fecal incontinence, irritable bowel syndrome, levator ani syndrome, migraine and tension headaches, refractory severe subjective tinnitus, temporomandibular joint syndrome, urinary incontinence, and neuromuscular rehabilitation of stroke and traumatic brain injury. Biofeedback is considered not medically necessary when used to improve emotional and physical health in non-diseased persons. EEG biofeedback is considered experimental, investigational, or unproven for migraine and tension headache, and several listed uses are experimental, including amygdala-related EEG neurofeedback for PTSD, HeartMath HRV biofeedback for headaches, InTandem for walking in chronic stroke, and surface EMG biofeedback for chronic ankle instability. Some Aetna plans exclude coverage of biofeedback.
Independence Blue Cross · Effective Jan 1, 2026Low impact
MA05.071, Remote Electrical Neuromodulation for Migraines
Independence Blue Cross reissued MA05.071 with no substantive changes to remote electrical neuromodulation (REN/Nerivio) coverage for migraine prevention. The policy maintains existing coverage criteria for adults (18+) and pediatric patients (8-17) who meet specific headache frequency and medication response thresholds, and continues to exclude acute migraine treatment as experimental/investigational. This is an annual review reissuance effective 01/01/2026 with no billing workflow changes required.
Independence Blue Cross · Effective Jan 1, 2026Low impact
05.00.86, Remote Electrical Neuromodulation for Migraines
Independence Blue Cross has reissued policy 05.00.86 with NO CHANGES to the existing coverage criteria for remote electrical neuromodulation (REN) devices like Nerivio for migraine prevention. The policy status remains MEDICALLY NECESSARY for qualifying adults (18+) and pediatric patients (8-17) who meet specific clinical criteria. This is an administrative reissuance for annual review purposes with an effective date of January 1, 2026.
Aetna · Identified Aug 18, 2026Low impact
Intra-oral Appliances for Headaches and Trigeminal Neuralgia (CPB 0688, reviewed 2025-12-29)
Aetna's Clinical Policy Bulletin 0688 (reviewed 2025-12-29, historical material first detected 2026-08-18) states that intra-oral appliances such as the NTI-tss are considered experimental, investigational, or unproven for headaches and trigeminal neuralgia, and lists dental and sleep-appliance codes plus ICD-10 headache and trigeminal neuralgia codes as not covered for these indications. Practices should treat these services as non-covered for the stated diagnoses, confirm current applicability on Aetna's site, and not bill them to Aetna for those indications without verifying the plan's current position.

Watch G43.001

Get one email when a payer policy names G43.001, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code G43.001?

There are 17 tracked policy changes affecting code G43.001, including updates from Independence Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G43.001?

Payers that have issued tracked updates for code G43.001 include: Independence Blue Cross, Aetna.

How do I get notified when code G43.001 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G43.001. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G43.001?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

MA05.071, Remote Electrical Neuromodulation for Migraines

05.00.86, Remote Electrical Neuromodulation for Migraines

Ziconotide (Prialt) (CPB 0712, reviewed 2026-10-14)

Intra-oral Appliances for Headaches and Trigeminal Neuralgia (CPB 0688, reviewed 2026-10-14)

Eptinezumab-jjmr (Vyepti) (CPB 0970, reviewed 2026-10-14)

Therapeutic Phlebotomy (CPB 0652, reviewed 2026-09-25)

Infrared Therapy (CPB 0604, reviewed 2026-09-09)

Neuropsychological and Psychological Testing (CPB 0158, reviewed 2026-03-20)

Hospitalization for the Initiation of Ketogenic Diet (CPB 0226, reviewed 2026-04-23)

Headaches: Nonsurgical Management (CPB 0462, reviewed 2026-07-23)

Fecal Bacteriotherapy (CPB 0844, reviewed 2026-03-25)

Eptinezumab-jjmr (Vyepti) (CPB 0970, reviewed 2025-12-09)

Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-06-03)

Biofeedback (CPB 0132, reviewed 2026-07-16)